{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T06:24:40Z","timestamp":1778135080602,"version":"3.51.4"},"reference-count":29,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2008,11,1]],"date-time":"2008-11-01T00:00:00Z","timestamp":1225497600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2008,11]]},"DOI":"10.1016\/j.leukres.2008.04.023","type":"journal-article","created":{"date-parts":[[2008,7,8]],"date-time":"2008-07-08T10:07:20Z","timestamp":1215511640000},"page":"1724-1734","source":"Crossref","is-referenced-by-count":11,"title":["Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy"],"prefix":"10.1016","volume":"32","author":[{"given":"Ju-Huei","family":"Chien","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jih-Luh","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rong-Long","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Cheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chan Ping","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.leukres.2008.04.023_bib1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0092-8674(05)80094-7","article-title":"BCR-ABL-induced oncongenesis in mediated by direct interaction with the SH2 domain of GRB-2 adaptor protein","volume":"75","author":"Pendergast","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.leukres.2008.04.023_bib2","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/j.1460-2075.1994.tb06319.x","article-title":"BCR-ABL oncoproteins bind directly to activator of the Ras signaling pathway","volume":"13","author":"Puil","year":"1994","journal-title":"EMBO J"},{"key":"10.1016\/j.leukres.2008.04.023_bib3","doi-asserted-by":"crossref","first-page":"31704","DOI":"10.1074\/jbc.271.49.31704","article-title":"P210 and P190 (BCR-ABL) induce the tyrosine phosphorylation and DNA binding activity of multiple specific STAT family members","volume":"271","author":"Ilaria","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2008.04.023_bib4","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1084\/jem.183.3.811","article-title":"Tyrosine phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by bcr\/abl","volume":"183","author":"Carlesso","year":"1996","journal-title":"J Exp Med"},{"key":"10.1016\/j.leukres.2008.04.023_bib5","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1182\/blood.V86.2.726.bloodjournal862726","article-title":"Phosphatidylinositol-3 kinase activity is regulated by BCR\/ABL and is required for the growth of Philadelphia chromosome-positive cells","volume":"86","author":"Skorski","year":"1995","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.023_bib6","first-page":"2049","article-title":"BCR-ABL tyrosine kinase activity regulates the expression of multiple genes implicated in the pathogenesis of chronic myeloid leukemia","volume":"60","author":"Deininger","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.04.023_bib7","first-page":"209","article-title":"Abl genes","volume":"989","author":"Ramakrishnan","year":"1989","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.leukres.2008.04.023_bib8","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1182\/blood.V99.5.1860","article-title":"Ph (+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation","volume":"99","author":"Hofmann","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.023_bib9","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1046\/j.1365-2141.2002.03708.x","article-title":"Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571","volume":"119","author":"Barthe","year":"2002","journal-title":"Br J Haematol"},{"key":"10.1016\/j.leukres.2008.04.023_bib10","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1182\/blood.V95.5.1758.005a41_1758_1766","article-title":"Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification","volume":"95","author":"Le Coutre","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.023_bib11","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1093\/jnci\/92.20.1641","article-title":"Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL (+) leukemic cells to the abl inhibitor STI571","volume":"92","author":"Gambacorti-Passerini","year":"2000","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.leukres.2008.04.023_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2796.2000.t01-1-00689.x","article-title":"Multidrug resistance in haematological malignancies","volume":"247","author":"Sonneveld","year":"2000","journal-title":"J Intern Med"},{"key":"10.1016\/j.leukres.2008.04.023_bib13","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1200\/JCO.20.1.325","article-title":"STI571: a paradigm of new agents for cancer therapeutics","volume":"20","author":"Mauro","year":"2002","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.leukres.2008.04.023_bib14","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1126\/science.1062538","article-title":"Clinical resistance to STI571 cancer therapy caused by BCR-ABL gene mutation of amplification","volume":"293","author":"Gorre","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.leukres.2008.04.023_bib15","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood.V99.9.3472","article-title":"High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR\/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance","volume":"99","author":"Branford","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.023_bib16","first-page":"5995","article-title":"Mutation in the ATP-binding pocket of the ABL kinase domain in a STI571-resistant BCR\/ABL-positive cell line","volume":"62","author":"Ricci","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.leukres.2008.04.023_bib17","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1182\/blood-2002-09-2896","article-title":"Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis","volume":"102","author":"Branford","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.023_bib18","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1535-6108(02)00096-X","article-title":"Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia","volume":"2","author":"Shah","year":"2002","journal-title":"Cancer Cell"},{"key":"10.1016\/j.leukres.2008.04.023_bib19","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1182\/asheducation-2002.1.111","article-title":"Chronic myelogenous leukemia","author":"Druker","year":"2002","journal-title":"Hematology"},{"key":"10.1016\/j.leukres.2008.04.023_bib20","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s004390051066","article-title":"A comparison of BRCA1 mutation analysis by direct sequencing, SSCP and DHPLC","volume":"105","author":"Gross","year":"1999","journal-title":"Hum Genet"},{"key":"10.1016\/j.leukres.2008.04.023_bib21","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1056\/NEJM200104053441402","article-title":"Activity of a specific inhibitor or the Bcr-Abl tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome","volume":"344","author":"Druker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.leukres.2008.04.023_bib22","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1182\/blood.V100.3.1014","article-title":"Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment","volume":"100","author":"Roche-Lestienne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.023_bib23","doi-asserted-by":"crossref","first-page":"32214","DOI":"10.1074\/jbc.M111525200","article-title":"Analysis of the structure basis of specificity of inhibition of the Abl kinase by STI571","volume":"277","author":"Corbin","year":"2000","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2008.04.023_bib24","doi-asserted-by":"crossref","first-page":"19585","DOI":"10.1074\/jbc.271.32.19585","article-title":"An activation mutation in the ATP binding site of the ABL kinase domain","volume":"271","author":"Allen","year":"1996","journal-title":"J Biol Chem"},{"key":"10.1016\/j.leukres.2008.04.023_bib25","doi-asserted-by":"crossref","first-page":"3498","DOI":"10.1182\/blood.V95.11.3498","article-title":"Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR\/ABL-transformed hematopoietic cell lines","volume":"95","author":"Weisberg","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.023_bib26","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood.V96.3.1070","article-title":"Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance","volume":"96","author":"Mahon","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2008.04.023_bib27","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S1470-2045(03)00979-3","article-title":"Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias","volume":"4","author":"Gambacorti-Passerini","year":"2003","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.leukres.2008.04.023_bib28","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/35085665","article-title":"New-age drug meets resistance","volume":"412","author":"McCormick","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.leukres.2008.04.023_bib29","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1182\/blood-2002-02-0360","article-title":"Early minimal residual disease (MRD) analysis during treatment of Philadelphia chromosome Bcr-Abl positive acute lymphoblastic leukemia with the Abl-tyrosine kinase inhibitor imatinib (STI571)","volume":"101","author":"Scheuring","year":"2003","journal-title":"Blood"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002245?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212608002245?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T22:25:40Z","timestamp":1588803940000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212608002245"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,11]]},"references-count":29,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2008,11]]}},"alternative-id":["S0145212608002245"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2008.04.023","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2008,11]]}}}